

Provisional Draft Agenda
46th meeting of the Committee for Socio-economic Analysis

10-12 March 2020
and
17-19 March 2020

**ECHA Conference Centre, Sisu meeting room (Telakkakatu 6,
Helsinki)**

Tuesday 10 March starts at 14.00
Thursday 12 March breaks at 17.30
Tuesday 17 March resumes at 14.00
Thursday 19 March ends at 17.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

SEAC/A/46/2019
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on SEAC-45 action points, written procedures and update on other ECHA bodies

For information

Item 5 – Restrictions

5.1 General restriction issues

- a) Report from the Restrictions Task Force

- b) Revision of the RAC and SEAC working procedure on opinion development

***Doc to be distributed
For information***

5.2 Restriction Annex XV dossiers

- a) Conformity and key issues discussion

- 1) Undecafluorohexanoic acid (PFHxA), its salts and related substances

For agreement

- b) Opinion development

- 1) Calcium cyanamide in fertilisers – second draft opinion

For discussion

- 2) Skin sensitisers in textile – third draft opinion

- 3) Microplastics – fifth draft opinion

- 4) Perfluorohexane-1-sulphonic acid, its salts and related substances – third draft opinion

- 5) Formaldehyde and formaldehyde releasers – fourth draft opinion

- 6) Five cobalt salts – fifth draft opinion

For discussion and agreement

- 7) Siloxanes (D4, D5 and D6) – draft final opinion

For discussion and adoption

5.3 Appointment of (co-)rapporteurs for restriction dossiers

For information

Item 6 – Authorisation

6.1 General authorisation issues

- a) Update on incoming/future applications

- b) Report from the Commission Workshop on AfAs (3 February 2020)

For information

6.2 Authorisation applications

- a) Discussion on key issues

- 1) 11 applications for authorisation from November 2019 submission window (OPE/NPE)

For discussion

- b) Agreement on draft opinion

- 1) 147_CTPht_Bilbaina (1 use)

- 2) 148_CTPht_DEZA (1 use)
- 3) 155_OPE_Siemens_2 (5 uses)
- 4) 156_OPE_Hospira (1 use)
- 5) 160_OPE_Merck_2 (1 use)
- 6) 162_OPE_LFB (1 use)
- 7) 163_OPE_Rentschler (1 use)
- 8) 170_OPE_DiaSorin (1 use)
- 9) 172_OPE_DIAGAST (1 use)
- 10) 174_OPE_Eli_Lilly (1 use)
- 11) 175_OPE_Rousselot (1 use)
- 12) 176_OPE_Abbott_1 (5 uses)
- 13) 180_OPE_NPE_Bio-Rad (4 uses)
- 14) 182_NPE_Abbott (1 use)
- 15) 186_OPE_NPE_Beckman (5 uses)
- 16) 187_OPE_AGC (2 uses)
- 17) 189_OPE_Lonza (1 use)
- 18) 190_OPE_TEVA (1 use)
- 19) 191_NPE_Sekisui (1 use)

For discussion and agreement

- c) Adoption of opinion
 - 1) CT_TES (1 use)
 - 2) OPE_Boehringer (1 use)

For discussion and adoption

- d) Status update
 - 1) AfAs agreed at SEAC-45
 - 2) 165_OPE_bioMerieux_2 (1 use)
 - 3) 184_OPE_Lilly (1 use)
 - 4) 185_OPE_NPE_Idexx (3 uses)

For information

6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)

***Doc to be distributed
For agreement***

Item 7 – AOB

- a) Update of the work plan

For information

Item 8 – Action points and main conclusions of SEAC-46

Table with Conclusions and Action points from SEAC-46

For adoption